Biotech | April 06, 2026
Biocon renames Irish step-down subsidiary as Biocon Biologics Ireland
Move aligns global biologics identity under the Biocon Biologics brand
Move aligns global biologics identity under the Biocon Biologics brand
Board approves five-year appointment, subject to shareholder nod through postal ballot
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Subscribe To Our Newsletter & Stay Updated
